Meeting Highlights

            Highlights from the San Antonio Breast Cancer Symposium, December, 2014:

1.)  Fulvestrant yields survival advantage in advanced breast cancer in the Phase II FIRST Trial.

2.)  Practice changing results from the SOFT Trial:  Ovarian suppression should be offered to women with breast cancer < age 35 in the adjuvant setting.

3.)  Low fat diet was shown to have significant PFS in women with Triple-Negative Breast Cancer, from the WINS Study.

4.)  Tamoxifen Preventative therapy yields continuing benefit in follow up data, now at 15 years duration.